Association of serum thymosin β4 with malnutrition-inflammation-atherosclerosis syndrome in peritoneal dialysis patients: a cross-sectional study

References

• Yeates K, Zhu N, Fenton ES, et al. Hemodialysis and peritoneal dialysis are associated with similar outcomes for end-stage renal disease treatment in Canada. Nephrol Dial Transplant. 2012;27(9):1–10.
   PubMed Web of Science ®Google Scholar
• Stevinkel P. Inflammatory and atherosclerotic interactions in the depleted uremic patient. Blood Purif. 2001;19:53–61.
   PubMed Web of Science ®Google Scholar
• Stevinkel P. Malnutrition and chronic inflammation as risk factors for cardiovascular disease in chronic renal failure. Blood Purif. 2001;19:143–151.
   PubMed Web of Science ®Google Scholar
• Dong J, Wang T, Wang H-Y. The impact of new comorbidities on nutritional status in continuous ambulatory peritoneal dialysis patients. Blood Purif. 2006;24(5–6):517–523.
   PubMed Web of Science ®Google Scholar
• Stenvinkel P, Heimbürger O, Paultre F, et al. Srtong association between malnutrition, inflammation and atherosclerosis in chronic renal faliure. Kidney Int. 1999;55(5):1899–1911.
   PubMed Web of Science ®Google Scholar
• Akdag I, Yilmaz Y, Gullulu M, et al. Clinical value of malnutrition-inflammation-atherosclerosis syndrome for long-term prediction of cadiovascular mortality with end-stage renal disease: a 5-year prospective study. Nephron Clin Pract. 2008;108(2):c99–c105.
   PubMedGoogle Scholar
• Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proc Natl Acad Sci U S A. 1981;78(2):1162–1166.
   PubMed Web of Science ®Google Scholar
• Tian Z, Yao N, Wang F, et al. Thymosin β4 suppresses LPS-Induced murine lung fibrosis by attenuating oxidative injury and alleviating inflammation. Inflammation. 2022;45(1):59–73.
   PubMed Web of Science ®Google Scholar
• Vasilopoulou E, Winyard PJ, Long DA, et al. The role of thymosinβ4 in kidney disease. Expert Opin Biol Ther. 2015;15(Suppl 1): s 187–90.
   Google Scholar
• Kassem KM, Vaid S, Rhaleb NE, et al. Tβ4-AcSDKP pathway: any relevance for the cardiovascular system? Can J Physiol Pharmacol. 2019;97(7):589–599.
   PubMed Web of Science ®Google Scholar
• Hong KO, Lee J, Hong SD, et al. Thymosin beta4 induces proliferation, invasion, and epithelial-to- mesenchymal transition of oral squamous cell carcinoma. Amino Acids. 2016;48(1):117–127.
   PubMed Web of Science ®Google Scholar
• Cavasin MA. Therapeutic potential of thymosin-β4 and its derivative N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) in cardiac healing after infarction. Am J Cardiovasc Drugs. 2006;6(5):305–311.
   PubMedGoogle Scholar
• He T, Jankowski V, Jankowski V, et al. Peptides in plasma, urine, and dialysate: toward unravelling renal peptide handling. Proteomics Clin Appl. 2021;15(1):e2000029.
   PubMed Web of Science ®Google Scholar
• Li W, Qing HD, Fang W, et al. Association of serum uric acid in hemodialysis patients. Chinese Journal of Nephrology. 2011;27(6):411–415.
   Google Scholar
• Zhou Q, Bajo MA, Selgas R, et al. Preventing peritoneal membrane fibrosis in peritoneal dialysis patients. Kidney Int. 2016;90(3):515–524.
   PubMed Web of Science ®Google Scholar
• Waniewski J, Stachowska-Pietka J, Flessner MF. Distributed modeling of osmotically driven fluid transport in peritoneal dialysis: theoretical and computational investigations. Am J Physiol Heart Circ Physiol. 2009;296(6):H1960–H1968.
   PubMed Web of Science ®Google Scholar
• Garosi G, Cappelletti F, Di Paolo N. Fibrosis and sclerosis: different disorders or different stages? Contrib Nephrol. 2006;150:62–69.
   PubMed Web of Science ®Google Scholar
• Davies SJ. Peritoneal solute transport and inflammation. Am J Kidney Dis. 2014;64(6):978–986.
   PubMed Web of Science ®Google Scholar
• Zuo YQ, Chun B, Fogo AB, et al. Thymosin β4 and its degradation product, AcSDKP, are novel reparative factors in renal fibrosis. Kidney Int. 2013 December;84(6):1166–1175.
   PubMed Web of Science ®Google Scholar
• Knop J, App C, Hannappel E. Antibodies in research of thymosin beta4: investigation of cross-reactivity and influence of fixatives. Ann N Y Acad Sci. 2012;1270:105–111.
   PubMed Web of Science ®Google Scholar
• Vasilopoulou E, Riley PR, Long DA. Thymosinβ4:a key modifier of renal disease. Expert Opin Biol Ther. 2018; Jul18(sup1):185–192.
   PubMed Web of Science ®Google Scholar
• Romero CA, Kumar N, Nakagawa P, et al. Renal release of N-acetyl-seryl-aspartyl -lysyl-proline is part of an antifibrotic peptidergic system in the kidney. Am J Physiol Renal Physiol. 2019; Jan 1316(1):F195–F203.
   PubMed Web of Science ®Google Scholar
• Myohanen TT, Tenorio-Laranga J, Männistö PT, et al. Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner. Br J Pharmacol. 2011;163(8):1666–1678.
   PubMed Web of Science ®Google Scholar
• Xu BJ, Shyr Y, Fogo AB, et al. Proteomic patterns and prediction of glomerulosclerosis and its mechanisms. J Am Soc Nephrol. 2005;16(10):2967–2975.
   PubMed Web of Science ®Google Scholar
• Pippin JW, Brinkkoetter PT, Cormack-Aboud FC, et al. Inducible rodent models of acquired podocyte diseases. Am J Physiol Renal Physiol. 2009;296(2):F213–F229.
   PubMed Web of Science ®Google Scholar
• Liao TD, Yang XP, Carretero OD, et al. N-acetyl-serylaspartyl-lysyl-proline attenuates renal injury and dysfunction in hypertensive rats with reduce adrenal mass: council for high blood pressure research. Hypertension. 2010; Feb55(2):459–467.
   PubMed Web of Science ®Google Scholar
• Ma LJ, Fogo AB. PAI-1 and kidney fibrosis. Front Biosci (Landmark Ed). 2009;1:14(6):2028–2041.
   Google Scholar
• Xian Z, Zhang YY. Malnutrition-inflammation-atherosclerosis syndrome and end-stage renal disease. Cjit W N. 2013;14(9):827–829.
   Google Scholar
• Muscaritoli M, Molfino A, Fanelli FR, et al.. Malnutrition and wasting in renal disease. Curr Opin Clin Nutr Metab Care. 2009;12(4):378–383.
   PubMed Web of Science ®Google Scholar
• Mushnick R, Fein PA, Mittman N, et al. Relationship of bioelectrical impedance parameters to nutrition and survival in peritoneal dialysis patients. Kidney Int Suppl. 2003;64(87):S53–S56.
   Google Scholar
• Fm R, Mzc S, Sgz B. Association between phase angle and coronary artery calcium score in patients on peritoneal dialysis. Front Nutr. 2022;9:912642.
   PubMed Web of Science ®Google Scholar
• Savino W. The thymus gland is a target in malnutrition. Eur J Clin Nutr. 2002;56(S3):S46–S49.
   PubMedGoogle Scholar
• Savino W, Dardenne M. Nutritional imbalances and infections affect the thymus: consequences on T-cell-mediated immune responses. Proc Nutr Soc. 2010;69(4):636–643.
   PubMed Web of Science ®Google Scholar
• El-Zayat SR, Sibaii H, Mahfouz NN, et al. Effect of vitamin a defificiency on thymosin-b4 and CD4 concentrations. J Genet Eng Biotechnol. 2018;16(1):57–61.
   PubMedGoogle Scholar
• Jotterand Drepper V, Kihm LP, Kälble F, et al. Overhydration is a strong predictor of mortality in peritoneal dialysis Patients-Independently of cardiac failure. PLoS One. 2016;11(7):e0158741.
   PubMed Web of Science ®Google Scholar
• Kirtchevsky SB, Cesari M, Phaor M. Inflammatory markers and cardiovascular health in older patients. Cardiovasc Res. 2005;66(2):65–75.
   Web of Science ®Google Scholar
• Swerdlow DI, Holmes MV, Kuchenbaecker KB, Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379(9822):1214–1224.
   PubMed Web of Science ®Google Scholar
• Wang AY, Lam CW, Chan IH, et al. Long-term mortality and cardiovascular risk stratification of peritoneal dialysis patients using a combination of inflammation and calcification markers. Nephrol Dial Transplant. 2009;24(12):3826–3833.
   PubMed Web of Science ®Google Scholar
• Yildiz G, Duman A, Aydin H, et al. Evaluation of association between atherogenic index of plasma and intima-media thickness of the carotid artery for subclinic atherosclerosis inpatients on maintenance hemodialysis. Hemodial Int. 2013;17(3):397–405.
   PubMed Web of Science ®Google Scholar
• Heidari B. C-reactive protein and other markers of inflammation in hemodialysis patients. Caspian J Inter Med. 2013;4(1):611–616.
   PubMedGoogle Scholar
• Smart N, Risebro CA, Riley PR, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and eovascularization. Nature. 2007;445(7124):177–182.
   PubMed Web of Science ®Google Scholar
• Peng H, Xu J, Rhaleb NE, et al. Thymosin-beta4 prevents cardiac rupture and improves cardiac function in mice with myocardial infarction. Am J Physiol Heart Circ Physiol. 2014;307(5):H741–H751.
   PubMed Web of Science ®Google Scholar
• Gupta RC, Wang MJ, Sabbah HN, et al. Thymosin β4 and its cleavage product Ac-SDKP are down-regulated in left ventricular myocardium of dogs with chronic heart failure. Circulation. 2014;130(suppl_2):13767.
   Google Scholar
• Sabbah HN, Gupta RC, Singh-Gupta V. Thymosin beta4 and its cleavage product Ac-SDKP are down-regulated in left ventricular myocardium of patients with advanced heart failure. Heart Lung Transplant. 2015;34(4):S89.
   PubMed Web of Science ®Google Scholar
• Wijayaratne D, Muthuppalaniappan VM, Davenport A. Serum CA125 a potential marker of volume status for peritoneal dialysis patients? Int J Artif Organs. 2021;44(12):1029–1033.
   PubMed Web of Science ®Google Scholar
• Bernstein KE, Shen XY, Fuchs S, et al. Different in vivo functions of the two catalytic domains of angiotensin-converting enzyme(ACE). Curr Opin Pharmacol. 2011;11(2):105–111.
   PubMed Web of Science ®Google Scholar
• Hu P, Li B, Liu J, et al. AcSDKP regulates cell proliferation through the PI3KCA/akt signaling pathway. PLoS One. 2013;8(11):e79321.
   PubMed Web of Science ®Google Scholar
• Frangogianns NG. Pathophysiology of myocardial infarction. Compr Physiol. 2015;5(4):1841–1875.
   PubMed Web of Science ®Google Scholar
• Prabhu SD, Frangogiannis NG. The biological basis for cardiac repair after myocardial infarction:from inflammation to fibrosis. Circ Res. 2016;119(1):91–112.
   PubMed Web of Science ®Google Scholar
• Wang F, He Y, Yao N, et al. Thymosin β 4 protects against cardiac damage and subsequent cardiac fibrosis in mice with myocardial infarction. Cardiovasc Ther. 2022;2022:1308651.
   PubMed Web of Science ®Google Scholar